Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2020 08:30 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Initiates Search for CEO

MINNEAPOLIS, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with...
January 24, 2020 15:00 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxelObjective Response Rate (ORR) was 62% by RECIST criteriaStudy expansion in patients with pancreatic cancer planned to begin...
December 23, 2019 09:00 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium

MINNEAPOLIS, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with...
November 13, 2019 08:15 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Provides a Business Update and Reports Q3 2019 Financial Results

Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort plannedNew U.S. sites added in anticipation of further clinical developmentCompany raised $3.1 million in new capital ...
August 13, 2019 07:30 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019

Enrollment in Third Cohort of PDA Combination Study is Encouraging Preliminary Efficacy Signals Improve with New Data Regarding Second CohortEntire $2.3 million Owed under...
July 22, 2019 08:00 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial

Preliminary Efficacy Signals Seen with SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxelDSMB Approves Enrollment of 3rd and Final Cohort MINNEAPOLIS, July 22, 2019 (GLOBE...
May 14, 2019 08:32 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019

Enrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical...
March 22, 2019 08:15 ET | Source: Sun BioPharma, Inc.

Sun BioPharma Provides Business Update and Files Annual Report for 2018

Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as President and Chief...
November 05, 2018 08:00 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. Provides a Business Update and Files Report for Q3 2018

Sun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with Metastatic Pancreatic...
November 01, 2018 08:00 ET | Source: Sun BioPharma, Inc.

Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach, FL

MINNEAPOLIS, Minn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases,...